Clinical Trials Now Enrolling
SONODYNAMIC THERAPY IN DIPG
A Phase 1/2 research study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in DIPG patients.
Visit ClinicalTrials.gov or use NCT identifier NCT05123534 to view inclusion criteria and additional study details.
AZD1390 FOR RECURRENT GLIOBLASTOMA
A Phase 0/1b clinical trial to evaluate AZD1390 in patients with recurrent glioblastoma.
Visit ClinicalTrials.gov or use NCT identifier NCT05182905 to view inclusion criteria and additional study details.
Trial EligibilityNIRAPARIB FOR NEWLY DIAGNOSED GLIOBLASTOMA
A Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with newly diagnosed glioblastoma.
Visit ClinicalTrials.gov or use NCT identifier NCT05076513 to view inclusion criteria and additional study details.
Trial ScreeningNIRAPARIB FOR RECURRENT GLIOMA (GRADES II-IV)
A Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with recurrent WHO Grade II, III, or IV glioma with IDH1 or IDH2 mutation and ATRX loss.
Visit ClinicalTrials.gov or use NCT identifier NCT05076513 to view inclusion criteria and additional study details.
Trial ScreeningSONODYNAMIC THERAPY IN RECURRENT HIGH-GRADE GLIOMA
A Phase 0 research study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in recurrent high-grade glioma patients
Visit ClinicalTrials.gov or use NCT identifier NCT04559685 to view inclusion criteria and additional study details.
Trial ScreeningPAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration and tumor effects.
Visit ClinicalTrials.gov or use NCT identifier NCT04614909 to view inclusion criteria and additional study details.
Trial ScreeningINFIGRATINIB FOR RECURRENT HIGH-GRADE GLIOMA
A Phase 0 study of infigratinib in recurrent high-grade glioma patients with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort
Visit ClinicalTrials.gov or use NCT identifier NCT04424966 to view inclusion criteria and additional study details.
Trial Screening Physician InformationABEMACICLIB PLUS LY3214996 FOR RECURRENT GLIOBLASTOMA
A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma patients scheduled for resection to evaluate central nervous system (CNS) penetration
Visit ClinicalTrials.gov or use NCT identifier NCT04391595 to view inclusion criteria and additional study details.
Trial Screening Physician InformationRIBOCICLIB FOR RECURRENT GLIOBLASTOMA
A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade glioma patients scheduled for resection
Visit ClinicalTrials.gov or use NCT identifier NCT02933736 to view inclusion criteria and additional study details.
Trial ScreeningRIBOCICLIB FOR RECURRENT MENINGIOMA
A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade meningioma patients scheduled for resection
Visit ClinicalTrials.gov or use NCT identifier NCT02933736 to view inclusion criteria and additional study details.
Trial Screening